Studies reveal age-related infectious disease patterns including higher symptomatic rhinovirus risk in adults over 60, polypharmacy complications in infectious disease patients, and significant underutilization of COVID-19 antivirals among older adults despite proven benefits.
University of Alberta researchers have identified the protease GlpG as a new drug target for antibiotic-resistant E. coli, which causes hundreds of thousands of UTI deaths annually. Inhibiting GlpG prevented bacterial adhesion and biofilm formation in laboratory studies. The discovery addresses a global health emergency as antimicrobial resistance projections show it could cause cancer-level deaths by 2050.
The U.S. FDA has accepted Gilead's application for an investigational once-weekly oral lenacapavir for HIV prevention, with a review date set for February 2027. Concurrently, PEPFAR and The Global Fund are expanding access to the twice-yearly injectable version to a total of 3 million people by 2028. Gilead will present new data on both lenacapavir and a novel bictegravir/lenacapavir combination at CROI 2026.
Biotech stocks Ocugen, Kodiak Sciences, and CytoDyn are experiencing market movements driven by clinical data and regulatory milestones, particularly Biologics License Application (BLA) filings. Ocugen saw a surge in short interest, Kodiak reached a 52-week high on positive trial results, and CytoDyn's stock remains volatile as it advances its monoclonal antibody pipeline.
Maryland biotech leaders outlined a strategy to scale the state's life sciences ecosystem, focusing on community building, investor attraction, and federal alignment. Meanwhile, 18 states face limited access to HIV treatment assistance programs due to stagnant federal funding amid rising costs.
Gilead Sciences reported Q1 2026 total product sales of $6.9 billion, up 5% year over year, with HIV revenue growing 10% to $5.0 billion. The company raised its full-year 2026 base business revenue guidance by $400 million to $29.4–$29.8 billion. Non-GAAP diluted EPS was $2.03, up 12%, while the company advanced its oncology and cell therapy pipeline.
South Africa will begin providing lenacapavir on June 5 after delays tied to postimportation testing, while Uganda has launched rollout of the twice-yearly HIV prevention injection in Lira.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
Pitt received $669.7 million in NIH funding in 2025 to rank No. 7 nationally. Penn Nursing received $17.9 million, ranking first among U.S. nursing schools.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07589985 |
Hep Mec Cohort in Zambia |
RECRUITING | |
| NCT07579247 |
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07574619 |
Improving Choice And Use Of Biomedical HIV Prevention For Women In Uganda: A Couples-based Approach |
RECRUITING | NA |
| NCT07569029 |
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies |
NOT_YET_RECRUITING | PHASE1 |
| NCT07564193 |
The Coach Mpilo Study: Evaluation of a Peer-led Intervention to Promote Engagement in HIV Care for Men Living With HIV |
NOT_YET_RECRUITING | NA |
| NCT07561658 |
TelePharm PrEP/PEP |
NOT_YET_RECRUITING | NA |
| NCT07553949 |
Leveraging Pharmacy Technicians to Advance the Reach of Modern Antiretroviral Therapy (PHARM ART) in Community Clinics |
NOT_YET_RECRUITING | NA |
| NCT07528573 |
HIV Prevention and Care Engagement in Nepal |
COMPLETED | NA |
| NCT07516691 |
Evaluation of a New Strategy to Approach the Transgender Sex Worker Populations and Their Clients for Access to a Preventive Sexual Health System Through the ORTIF Digital Teleconsultation Solution |
NOT_YET_RECRUITING | |
| NCT07510048 |
Combatting HIV Or Other STIs Early (CHOOSE) |
NOT_YET_RECRUITING | PHASE2 |
